Nicola Low is an infectious disease epidemiologist with a background in genitourinary medicine and public health. Her main research interests are in the evaluation of screening interventions for the prevention of bacterial STIs, estimation of the burden of STIs and diagnostics for antimicrobial-resistant STIs

Suhella Tulsiani Drud, PhD. is an infectious disease biologist with expertise in microbiology, epidemiology and public health. After several years working at Queensland Health for the surveillance and diagnosis of leptospirosis, she currently works at the SSI, Denmark with the national surveillance of Mycoplasma genitalium.

William is a Clinical Development Director within the Infectious Diseases Clinical Research and Early Programs team at GSK.  He trained as a physician in north-west England and completed a PhD in Translational Medicine at the University of Manchester.  He continues to practice as an honorary consultant at Oxford University Hospitals.

Dr Alison Luckey, Associate Director of Medical Science, at GARDP, is a Pharmaceutical Physician and Fellow of the Faculty of Pharmaceutical Medicine. She has worked extensively in early phase drug development across a number of therapeutic areas and the last 11 years in late phase development of anti-infectives.

William M. Geisler, M.D., M.P.H, is a Professor of Medicine and Epidemiology in the Division of Infectious Diseases at the University of Alabama at Birmingham. He is an internationally recognized expert on chlamydia and Mycoplasma genitalium and has over 20 years of experience in the evaluation and management of STIs.

Director of the global WHO Collaborating Centre for STIs, Örebro, Sweden. Professor at Örebro University, Sweden and Honorary Professor at University College London, UK. Main research: especially N. gonorrhoeae but also, e.g., C. trachomatis, M. genitalium, syphilis. >470 PubMed-indexed international publications and numerous international guidelines and scientific chapters.

Associate Professor Fabian Kong is a pharmacist and sexual health epidemiologist currently working to optimise treatments for STIs, particularly for oral gonorrhoea using drug pharmacokinetics. He is also leading the development of the world's first oral human tissue model of oral gonorrhoea infection to screen emerging treatments to treat oral gonorrhoea.